Clinical significance of 123I-MIBG myocardial scintigraphy in patients with hypertrophic cardiomyopathy

Kakuigaku

Volumn 34, Issue 9, 1997, Pages 807-814

  Ido, Akira ^a   Hasebe, Naoyuki ^a   Nakamura, Hideki ^a   Om, Shinji ^a   Tsuji, Shiro ^a   Yokoyama, Ayumi ^a   Kido, Shinsuke ^a   Ishii, Yoshinao ^a   Kawamura, Yuichiro ^a   Yamashita, Hirohisa ^a   Kikuchi, Kenjiro ^a   Yamamoto, Wakako ^b   Shuuke, Noriyuki ^b   Aburano, Tamio ^b  

^a Niigata University   (Japan)

^b ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

123I metaiodobenzylguanidine (MIBG); Hypertrophic cardiomyopathy; Myocardial sympathetic function

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; NORADRENALIN; (3 IODOBENZYL)GUANIDINE; DIAGNOSTIC AGENT; RADIOACTIVE IODINE;

ADRENERGIC SYSTEM; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG UPTAKE; FEMALE; HEART; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE WALL; HEART SCINTISCANNING; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MALE; MEDIASTINUM; NORADRENALIN BLOOD LEVEL; SYMPTOM; MIDDLE AGED; SCINTISCANNING;

3-IODOBENZYLGUANIDINE; CARDIOMYOPATHY, HYPERTROPHIC; FEMALE; HEART; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED;

EID: 0030609059     PISSN: 00227854     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Laks MM, Morady F, Swan HJC: Myocardial hypertrophy produced by chronic infusion of subhypertensive doses of norepinephrine in the dog. Chest 64: 75-78, 1973
2. Perloff JK: Pathogenesis of hypertrophic cardiomyopathy: Hypotheses and speculations. Am Heart J 101: 219-226, 1981
3. Brush JE, Eisenhofer G, Garty M, Stull R, Maron BJ, Cannon RO, et al: Cardiac norepinephrine kinetics in hypertrophic cardiomyopathy. Circulation 79: 836-844, 1989
4. 123I-metaiodobenzylguanidine (MIBG) uptake in hypertrophic cardiomyopathy. Am Heart J 119: 1329-1337, 1990
5. Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE: A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled metaiodobenzylguanidine (MIBG). Nucl Med Commun 13: 513-521, 1992
6. 131I]iodobenzyl-guanidine (I-131 MIBG) and circulating catecholamines in suspected pheochromocytoma. J Nucl Med 24:1127-1134, 1983
7. Maron BJ, Bonow RO, Cannon RO, Leon MB, Epstein SE: Hypertrophie cardiomyopathy: Interrelations of clinical manifestations, pathophisiology and therapy. N Engl J Med 316: 780-789, 1987
8. Morozumi T, Kusuoka H, Fukuchi K, Tani A, Uehara T, Matsuda S, et al: Myocardial iodine- 123-metaiodobenzylguanidine images and autonomie nerve activity in normal subjects. J Nucl Med 38: 49-52, 1997
9. Morozumi T, Fukuchi K, Uehara T, Kusuoka H, Hori M, Nishimura T: Abnormal iodine-123-MIBG image in healthy volunteers. J Nucl Med 37: 1686-1688, 1996
10. Sisson JC, Bolgos G, Johnson J: Measuring acute changes in adrenergic nerve activity of the heart in the living animal. Am Heart J 121: 1119-1123, 1991
11. Schomig A: Catecholamines in myocardial ischemia: Systemic and cardiac release. Circulation 82 (suppl II): 11-13-11-22, 1990
12. Koga Y, Itaya K, Toshima H: Prognosis in hyper-trophic cardiomyopathy. Am Heart J 108: 351-359, 1984
13. Maron BJ, Savage DD, Wolfson JK, Epstein SE: Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: A prospective study. Am J Cardiol 48: 252-257, 1981
14. McKenna WJ, England D, Doi YL, Deanfield JE, Oakley C, Goodwin JF: Arrhythmia in hypertrophic cardiomyopathy: I. Influence on prognosis. Br Heart J 46: 168-172, 1981
15. 123I-Meta-Iodobenzylguanidine Scintigraphy. Circulation 89:667-683, 1994